Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer

Keyphrases

• Cisplatin 100%
• Advanced Ovarian Cancer 100%
• Profound Sensorineural Hearing Loss 100%
• One-cycle 100%
• Ototoxicity 50%
• Chemotherapy Regimen 25%
• Epithelial Ovarian Cancer 25%
• Paclitaxel 25%
• Intravenous Administration 25%
• Counseling 25%
• Platinum-based Chemotherapy 25%
• Overall Survival 25%
• Specific Risk 25%
• Sudden Sensorineural Hearing Loss (SSNHL) 25%
• Treatment Initiation 25%
• Intraperitoneal Administration 25%
• Alternative Agents 25%
• Systemic Steroids 25%
• Device Implantation 25%
• High-frequency Range 25%
• Intraperitoneal Infusion 25%
• Bilateral Sensorineural Hearing Loss 25%
• Steroid Taper 25%

Nursing and Health Professions

• Ovary Cancer 100%
• Perception Deafness 100%
• Cisplatin 100%
• Ovary Carcinoma 50%
• Intraperitoneal Drug Administration 50%
• Ototoxicity 50%
• Patient Counseling 25%
• Overall Survival 25%
• Paclitaxel 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Cisplatin 100%
• Ovary Cancer 100%
• Perception Deafness 100%
• Chemotherapy 50%
• Ototoxicity 50%
• Ovary Carcinoma 50%
• Paclitaxel 25%
• Overall Survival 25%